Background: Multidrug resistance (MDR) mediated by expression of MDR1 P-glycoprotein (Pgp) represents one of the best characterized barriers to chemotherapy in cancer patients. Positron emission tomography (PET) agents for analysis of Pgp-mediated drug transport activity in vivo would enable noninvasive assessment of chemotherapeutic regimens and MDR gene therapy.
Introduction
Resistance of malignant tumors to chemotherapeutic agents is a major cause of treatment failure in patients with cancer [1, 2] . One resistance phenotype, known as multidrug resistance (MDR), is characterized by the failure to respond to a variety of structurally and functionally diverse natural product cytotoxic and xenobiotic agents. MDR1 P-glycoprotein (Pgp), a 140-180 kDa plasma membrane transporter [3, 4] , is one of the best characterized mediators of multidrug resistance and is reported to alter the membrane permeability to cytotoxic compounds and/or enhance the efflux of these agents out of cancer cells [1, 2] . Identification a priori of the molecular target of a given therapeutic regimen, such as Pgp, is becoming increasingly common to select patients most likely to benefit from a given therapy. In addition, transgenic expression of the MDR1 gene has been explored for hematopoietic cell protection in the context of cancer chemotherapy [5] [6] [7] wherein Pgp could protect hematopoietic progenitor cells from chemotherapy-induced myelotoxicity. Indeed, hematopoietic cells transduced via retroviral-mediated transfer of the MDR1 gene have shown preferential survival after treatment of the animal with MDR drugs [7] . Methods to interrogate Pgp transport activity have therefore been sought [8] . In this regard, various single photon emission computed tomography (SPECT) radiopharmaceuticals exemplified by 99m Tc-Sestamibi [9] , 99m TcQ-58 [10] , 99m Tc-Tetrofosmin [11] [12] [13] and 99m Tc-Furifosmin [12, 14] have been validated as transport substrates for MDR1 Pgp, enabling noninvasive imaging of Pgp-mediated transport activity in vivo. To exploit the greater sensitivity and quantification capabilities of positron emission tomography (PET), however, radiopharmaceuticals of short half-life isotopes are desired. Based on structures of known MDR cytotoxic drugs or classic modulators, several 11 C-labeled PET agents [15] [16] [17] or potentially 11 C-labeled compounds [18, 19] targeting Pgp have been reported. Although promising preliminary data have been generated, the agents suffer from modest radiochemical yields and complex pharmacokinetics in vivo mediated, at least in part, by rapid metabolism of the radiolabeled compounds.
We sought an alternative strategy focused on discovering a nonmetabolized Pgp-targeted PET agent. Schiff-base ligands [20] [21] [22] and amine phenol ligands [23, 24] possessing an N 4 O 2 donor core are well known. Gallium(III) complexes of selected Schiff-base ligands show potential as positron-emitting radiopharmaceuticals for use in myocardial perfusion imaging [25] [26] [27] [28] . In addition, various stable Ga(III) complexes of this class of Schiff-base phenolic ligands also possess cytotoxic activity against tumor cells which is modified by expression of MDR1 Pgp [29] , suggesting that the compounds might be recognized as transport substrates of Pgp. Here we report the synthesis, characterization, and crystal structures of the two most favorable Pgp-targeted Ga(III) complexes, (bis(3-ethoxy-2-hydroxy-benzylidene)-N,N′-bis(2,2-dimethyl-3-aminopropyl)ethylenediamine)-gallium(III) perchlorate (6 6) and (bis(5-ethoxy-2-hydroxy-benzylidene)-N,N′-bis(2,2-dimethyl-3-aminopropyl)ethylenediamine)-gallium(III) iodide (7 7), along with tumor cell transport profiles and murine biodistributions indicating the potential for PET imaging of MDR1 Pgp-mediated transport activity in vivo.
Results and discussion

Chemistry
Compounds 6 6 and 7 7 were synthesized as shown in Figure 1 . Bis(N,N′-amino-2,2-dimethylpropane)ethylenediamine 1 1 was obtained by reacting dibromoethane and 2,2-dimethylpropane-1,3-diamine at room temperature. Synthetic scheme for Ga(III) complexes of hexadentate bis(salicylaldimine) ligands, where R 3 = OEt, R 5 = H for 3-ethoxy-ENBDMPI (6) or R 3 = H, R 5 = OEt for 5-ethoxy-ENBDMPI (7) 2-Hydroxy-3-ethoxy-benzaldehyde (2 2) was commercially available. However, 2-hydroxy-5-ethoxy-benzaldehyde (3 3) was obtained through a reaction involving 4-ethoxyphenol and paraformaldehyde using 10-20% tin(IV) chloride and trioctylamine in toluene [30] . The heptadentate precursors H 3 3-Eabi (4 4; 2-(2-hydroxy-3-ethoxyphenyl)-1,3-bis[4-aza-5-(2′-hydroxy-3′-ethoxyphenyl)2′′,2′′′-dimethyl-but-4′ -ene-1′-yl]-1,3-imidazolidine) and H 3 5-Eabi (5 5; 2-(2-hydroxy-5-ethoxyphenyl)-1,3-bis[4-aza-5-(2′-hydroxy-5′-ethoxyphenyl)2′′,2′′′-dimethyl-but-4′-ene-1′-yl]-1,3-imida zolidine). were obtained through condensation of compounds 2 2 or 3 3 and 1 1 in appropriate molar ratios using procedures described previously (Figure 1 ) [27, 29] . The presence of resonance signals at 3.78 and 3.70 ppm in the 1 H NMR spectra and 91.3 and 91.8 ppm in the proton decoupled 13 C NMR of 4 4 and 5 5, assigned to benzylic protons and carbons, respectively, suggested formation of the expected fivemembered imidazolidine rings. Furthermore, proton decoupled 13 C NMR of 4 4 and 5 5 recorded in CDCl 3 at room temperature demonstrated 24 resonance signals supporting formation of the desired precursors. On treatment of precursors 4 4 and 5 5 with gallium(III)acetylacetonate in ethanol, cleavage of the imidazolidine ring took place leading to formation of metal complexes. The aldimino protons were shifted downfield compared with the precursors and appeared at 8.19 and 8.14 ppm in 6 6 and 7 7, respectively, suggesting the coordination of the imine with the central gallium atom. Furthermore, the appearance of slightly broad singlets assigned to amine protons at 4.90 and 4.82 ppm in 6 6 and 7 7, respectively, were indicative of cleavage of the imidazolidine ring, thereby providing secondary amine nitrogens for coordination with the central metal core. Furthermore, although the cleaved precursors yield achiral and flexible free ligands, these ligands form rigid complexes upon coordination with Ga(III) (Figure 1 ), as evident from the series of multiplets in the hydrocarbon region. We ascribe these multiplets to chirality of the coordinated amine nitrogens. Furthermore, the chemical shifts of aldimino and amine protons, including a series of overlapping signals resulting from the hydrocarbon backbone, are in accord with earlier reported gallium complexes [26, 27, 29] . The presence of a single set of signals due to aromatic rings and aldimino protons in 1 H NMR spectra combined with 15 resonance signals in 13 C NMR spectra for 6 6 and 7 7 suggest the structure is symmetrical in solution [29] .
Crystals suitable for X-ray crystallography were grown by slow diffusion of ether in methanol over 3-4 days and slow evaporation of methanol at room temperature for 6 6 and 7 7, respectively. The Oak Ridge Thermal Ellipsoid Plot (ORTEP) drawings of 6 6 and 7 7 are shown in Figures 2  and 3 , respectively, along with selected bond angles and interatomic distances. The crystal structure provided direct evidence that gallium is coordinated symmetrically and simultaneously to the N 4 O 2 donor core of the ligand. The structure revealed that the central gallium is hexacoordinated involving two phenoxy oxygens (O1 and O2), two secondary amine nitrogens (N2 and N3) and two imine nitrogens (N1 and N4) with overall trans-pseudooctahedral geometry. Compared with the closest gallium(III) structural analog [27] , the interatomic distances of the Ga-O or Ga-N involved in the coordination sphere are similar and suggest comparable stability of the complexes. In addition, radio-thin layer chromatography (TLC) analysis of 67 Ga-labeled complexes 6 6 and 7 7 stored in saline:ethanol (90:10) for up to four days demonstrated only parent compound, further documenting stability of the complexes under aqueous conditions. As with the previously reported gallium(III) complex [27] (11); O1-Ga-N4, 91.87 (11); O2-Ga-N2, 87.75 (11); O2-Ga-N3, 93.45 (11); C1-O1-Ga, 125.6 (2); C22-O2-Ga, 124.1 (2); distances (Å), Ga-O1, 1.933(2); Ga-O2, 1.923 (2); Ga-N1, 2.056 (3); Ga-N2, 2.091 (3); Ga-N3, 2.104 (3); Ga-N4, 2.053 (3); O1-C1, 1.318 (4); O2-C22, 1.322 (4).
agreement to values observed previously [27, 31] , suggesting a mildly distorted octahedral geometry around the gallium. The smallest angle N2-Ga-N3 can be attributed to the restrictions of the five-membered chelate ring involving N(2), C(11), C (12) , N(3) and Ga. In comparison with the 3-ethoxy substituted compound 6 6 ( Figure 2 ), the 5-ethoxy analog 7 7 ( Figure 3 ) was highly similar in its distances and angles around the coordination sphere. However, C1-O1-Ga and C22-O2-Ga are 123.4(3)° and 122.0(2)°, respectively, and are 2° more acute in 7 7 compared to 6 6, suggesting slight variation in the positions of the peripheral constituents of each molecule, including the aromatic rings.
Cell transport assays
Radiolabeled 67 Ga complexes were obtained via 67 Ga(acetylacetonate) 3 and precursors 4 4 and 5 5 in ethanol at 80°C for 30 min using published procedures [27] . Final reaction mixtures were passed through nylon syringe filters (0.2 µm) and silica to remove excess ligand. Synthesis and workup could be accomplished in less than an hour, an interval of significant practical value for potential PET radiopharmaceuticals labeled with 68 Ga (t 1/2 = 68 min), which is obtained from commercially available 68 Ge (t 1/2 = 271d) generators. Compounds were assessed for their radiopharmaceutical purity by radio-TLC [methanol:saline, 90:10; R f :0.47(6 6), 0.48 (7 7)] and found to be > 95% pure.
67 Ga(III) complexes were evaluated for their MDR1 Pgpmediated transport activity in a whole-cell transport assay using drug-sensitive human epidermal carcinoma KB-3-1 cells and the colchicine-selected MDR derivative KB-8-5 cells as described previously [12, 32] . KB-3-1 cells do not express Pgp, whereas KB-8-5 cells express modest levels of Pgp as documented by Western blot analysis with mAb C219 [10] . Net cell content of many hydrophobic cationic tracers transported by Pgp is a function of both passive potential-dependent influx and transportermediated efflux [33] . Accordingly, favorable cationic 67 Ga complexes should highly penetrate KB-3-1 cells as result of the inwardly directed electrochemical driving forces [32] . As a further test of membrane potentialdependent influx, incubation of KB-3-1 cells in 120 mm K + /20 mM Cl -buffer containing the potassium ionophore valinomycin (1 µg/ml) has been shown to collapse mitochondrial and plasma membrane-potentials toward zero, and reduce net tracer uptake of membrane potentialresponsive hydrophobic cations [9, 34] . Net accumulation of the 67 Ga complexes should, therefore, be reduced in high K + /valinomycin buffer, and furthermore, tracer levels greater than that expected from equilibrium distribution into the water spaces under these conditions provide one measure of nonspecific adsorption to hydrophobic compartments within the cells [9] . Conversely, MDR1-Pgp-mediated outward transport of candidate 67 Ga complexes would be expected to decrease net cellular accumulation in KB-8-5 cells compared with KB-3-1 cells. In addition, the potent MDR1 Pgp antagonist GF120918 [33, 35] should enhance tracer accumulation in KB-8-5 cells by inhibiting the outward transport function of Pgp. Desirable MDR1 targeted complexes would therefore have the following properties: low nonspecific binding to membranes and hydrophobic compartments of cells; high distinction in net uptake levels between drug-sensitive cells and MDR cells; and significant enhancement of uptake in MDR cells upon addition of an MDR antagonist [12] .
In drug-sensitive KB-3-1 cells, the 3-ethoxy-substituted 67 Ga-complex 6 6 demonstrated plateau accumulation of 410 ± 28 fmol (mg protein) -1 (nM o ) -1 (n = 4), 55-fold greater than drug-resistant KB-8-5 cells (Figure 4a ). This was similar to the 48-fold difference (Figure 4c with 99m Tc-Sestamibi (Cardiolite ™ , hexakis(2-methoxyisobutylisonitrile)technetium(I) chloride), a previously validated agent tested under identical conditions [12] , and indicated that 6 6 was an avid transport substrate recognized by human MDR1 Pgp. In KB-3-1 cells, accumulation of 6 6 was 4.5-fold greater in control buffer than in the presence of high K + /valinomycin buffer, consistent with a significant response to depolarization of membrane potential. The final cell accumulation value was 91.2 ± 7.9 fmol (mg protein) -1 (nM o ) -1 (n = 4), greater than the value expected based on the cell water space estimated for these cells (5.4 µl/mg protein [12] ) implying a significant level of nonspecific adsorption of the complex to hydrophobic components within the cells. Addition of GF120918 at a concentration known to maximally inhibit Pgp (300 nM [10] ) enhanced cellular accumulation of 6 6 in MDR cells towards that observed in drug-sensitive cells, again consistent with a favorable transport profile.
Using the same techniques, we also radiolabeled the 3-methoxy analog 8 8 and the 4,6-dimethoxy analog 9 9 of the non-substituted hydrocarbon backbone ligands ( Figure 5 ) [29] . In comparison to 6 6, the drug-sensitive/drug-resistant cell uptake ratios were significantly less for these Ga(III) complexes (30 min cell uptake [fmol (mg protein) -1 (nM o ) -1 ] in KB-3-1 cells, in KB-8-5 cells, and KB-3-1/ KB-8-5 ratio: 8 8, 47 ± 5, 17 ± 1, 2.8; 9 9, 252 ± 20, 42 ± 2, 6.0). Thus the methyl substitutions in the hydrocarbon backbone coupled with the ethoxy functionality of 6 6 significantly improved the transport profile of the complex.
Variation in the position of the ethoxy group to the 5 position on the aromatic ring resulted in a less robust Pgpmediated transport profile, however (Figure 4b ). The 5-ethoxy-substituted 67 Ga-complex 7 7 showed only a 23-fold greater accumulation in drug-sensitive KB-3-1 cells compared with KB-8-5 cells, and furthermore, addition of GF120918 to drug-resistant KB-8-5 cells enhanced accumulation of 7 7 to a lesser degree. Of note, 7 7 showed a similar response as 6 6 to high K + /valinomycin buffer, suggesting a Research Paper Probing P-glycoprotein transport activity with gallium(III) complexes Sharma et al. 339
Figure 5
Structures of [(3-methoxy-ENBPI) 67 Ga] + (8) and [(4,6-dimethoxy-ENBPI) 67 Ga] + (9) . 
Biodistribution studies in mdr1a/b (-/-) mice
To demonstrate the potential use of radiolabeled Ga complexes as imaging markers of Pgp-mediated transport in vivo, we performed quantitative pharmacokinetic analysis in mice following intravenous injection of the tracer. Mice have two isoforms of Pgp (mdr1a and mdr1b) which confer multidrug resistance [36] . The drug-transporting mdr1a Pgp isoform is expressed in capillary endothelial cells of the brain wherein the protein is a major component of the blood-brain barrier [37] . Here, Pgp limits entry of a variety of amphipathic compounds into the central nervous system [36] . Drug-transporting Pgp isoforms are also expressed along the biliary cannalicular surface of hepatocytes wherein the transporters function to secrete substrates into the bile [36] . In this regard, mdr1a/1b (-/-) gene-disrupted mice, which have no drug-transporting Pgp, are a robust model for evaluation of candidate MDR agents by interrogating net tracer accumulation into brain and liver tissues [10] .
Thus, we analyzed initial tissue uptake and retention of 67 Ga-complex 6 6 in mdr1a/1b (-/-) mice in comparison to wild-type FVB mice ( Figure 6 ). Relative to wild-type mice, mdr1a/1b (-/-) mice showed tenfold more 67 Gacomplex 6 6 in brain parenchyma 5 minutes after injection of the complex (Figure 6b) . Additionally, the area under the curve from 5-120 minutes (AUC 5-120 ) of 6 6 in mdr1a/1b (-/-) brain was 62.5 ± 16.1 µCi (injected µCi) -1 (g tissue) -1 × 100 × min (n = 8), a value 17-fold greater than wild-type mice (p < 0.005). By contrast, blood retention of 6 6 in mdr1a/1b (-/-) mice was 29.4 ± 8.7 µCi (injected µCi) -1 (g tissue) -1 × 100 × min, only 1.2-fold that of wildtype control (p > 0.5; Figure 6a ). Because blood flow to the brain does not differ between mdr1 gene disrupted and wild-type mice [38] , the marked enhancement in initial penetration and retention of 6 6 in brain tissue of mdr1a/1b (-/-) mice cannot be attributed to differences in cerebral perfusion. Pilot imaging experiments using planar scintigraphy also demonstrated increased visualization of 67 Ga-complex 6 6 in the brains of mdr1a/1b (-/-) mice, compared to control (data not shown), thus showing promise for eventual quantitative imaging by clinical or microPET [39] . Furthermore, 6 6 shows 3-5-fold greater differences in brain AUC between wild-type and mdr1 (-/-) mice than 99m Tc-Sestamibi [40] , 99m TcQ-58 [10] and 99m Tc-Tetrofosmin [13] , further documenting its potential superiority for imaging Pgp activity in vivo.
In liver, initial accumulation of 6 6 was comparable between mdr1a/1b (-/-) and wild-type mice (Figure 6c ). However, liver clearance was markedly delayed in mdr1a/1b (-/-) mice consistent with blockade of Pgp-mediated biliary secretion of the tracer. The AUC 5-120 of 6 6 in liver tissue of mdr1a/1b (-/-) mice was 2465 ± 440 µCi (injected µCi) -1 (g tissue) -1 × 100 × min, twofold greater than wild-type mice. These data further validate 67 Ga-complex 6 6 as a substrate for Pgp in vivo and show its potential as a molecular imaging probe of transporter function and inhibition in the living organism.
Significance
One of the best characterized barriers to chemotherapy in cancer patients is multidrug resistance (MDR) mediated by expression of the MDR1 P-glycoprotein (Pgp). We wanted to develop agents for use in positron emission tomography (PET) to allow noninvasive assessment of chemotherapy regimens and MDR gene therapy. Selected Schiff-base phenolic complexes of Ga(III) are shown to be probes of MDR1 Pgp-mediated transport activity. Variation in the position of the ethoxy group from para to ortho with respect to the Ga-O-C bond increased MDR1 Pgp recognition in vitro, suggesting that the unique MDR1 Pgp transport properties of the 3-ethoxy Ga(III)-complex 6 6 lie in the spatial orienta- tion of the peripheral constituents of the molecule rather than within the inner coordination sphere. Biodistribution analysis demonstrated that differences in Pgp transport activity could be readily detected with tracer concentrations of 67 Ga-labeled 6 6 in mdr1a/1b (-/-) genedisrupted mice compared to control, and, therefore, 68 Ga analogs of 6 6 may provide useful scaffolds to generate a PET radiopharmaceutical for quantifying the functional status of Pgp in tumors and tissues in vivo. 
Materials and methods
General methods
Bis(N,N′-amino-2,2-dimethylpropane)ethylenediamine (1)
Potassium hydroxide (4.0 g, 71.3 mmol) was added to dibromoethane (3.0 g, 15.9 mmol) in acetonitrile (35 ml 
2-hydroxy-5-ethoxy-benzaldehyde (3)
4-Ethoxyphenol (1.28 g, 9.26 mmol) and trioctylamine (1.64 g, 4.63 mmol) dissolved in toluene (20 ml) were treated with dropwise addition of tin tetrachloride (1.85 ml, 1.0 M) and stirred for 30 min at room temperature. Paraformaldehyde (0.83 g, 27.8 mmol) was added and refluxed at 90°C for 10 h. The contents were cooled to room temperature, hydrolyzed and acidified to pH 2.5, extracted with methylene chloride (3 × 100 ml), dried over anhydrous sodium sulfate, filtered, evaporated, and the residue purified on silica using 1% ethylacetate in hexane. 
2-(2-hydroxy-3-ethoxyphenyl)-1,3-bis[4-aza-5-(2′-hydroxy-3′-ethoxyphenyl)2′′,2′′′-dimethyl-but-4′-ene-1′-yl]-1,3-imidazolidine (H 3 3-Eabi; 4)
Compound 4 was prepared using methods described previously [27, 29] . 1 
2-(2-hydroxy-5-ethoxyphenyl)-1,3-bis[4-aza-5-(2′-hydroxy-5′-ethoxyphenyl)2′′,2′′′-dimethyl-but-4′-ene-1′-yl]-1,3-imidazolidine (H 3 5-Eabi; 5)
dimethyl sulfoxide (DMSO). Final concentration of DMSO in experimental buffers was <1%, which has been found to have no effect on net uptake of tracer complexes in cultured cells [42] . Transport assays. Coverslips with confluent cells were used for studies of cell transport and kinetics as described previously [9] . In brief, cells were removed from culture media and washed for 15-30 s in MEBSS. Accumulation experiments were initiated by immersing coverslips in 60 mm glass Pyrex dishes containing 4 ml loading solution consisting of MEBSS with 1-6 nM [ 67 Ga-complex] (300-900 pmol/mCi; 1-2 µCi/ml). Coverslips with cells were removed at various times, rinsed 3 × in 25 ml ice-cold isotope-free solution for 8 s to clear extracellular spaces, and placed in 35 mm plastic Petri dishes. Cells were extracted in 1% sodium dodecylsulfate with 10 mM sodium borate before protein assay by the method of Lowry et al. [44] using bovine serum albumin as the protein standard. Aliquots of the loading buffer and stock solutions also were obtained for standardizing cellular data with extracellular concentration of each Ga complex. Cell extracts, stock solutions and extracellular buffer samples were assayed for gamma activity in a well-type sodium iodide gamma counter (Cobra II, Packard, Meridan, Conn.). Absolute concentration of total Ga complex in solution was determined from the activity of stock solutions and specific activity of 67 Ga. Data are reported as fmol Ga complex (mg protein) -1 (nM o ) -1 as previously described, with (nM o ) -1 representing total concentration of Ga-complex in the extracellular buffer [45] .
Biodistribution studies
Vertebrate animal procedures were approved by the appropriate institutional review committee. Distribution of 67 Ga complex in the blood, liver and brain tissues of parental strain FVB mice (FVB/NTacfBR) and FVB mdr1a/1b (-/-) gene knockout mice (FVB/TacfBR-[KO]mdr1a-[KO]mdr1bN7) (Taconic, Germantown, NY) was determined as described previously [10, 46] . 67 Ga-complex was diluted in 90:10 saline:ethanol to a final concentration of 20 µCi/ml. Mice were anesthetized by metafane inhalation and injected with 2 µCi of radiotracer via bolus injection through a tail vein. Animals were sacrificed by cervical dislocation at 5, 15, 60 and 120 min post-injection (n = 2-4 each). Blood samples were obtained by cardiac puncture and tissues harvested rapidly. Gamma activity in organ samples was counted for 1 min, or until two standard deviations of sampling were below 0.5%. Data are expressed as percent of injected dose per gram of tissue [(tissue µCi) (injected µCi) -1 (g tissue) -1 × 100]. From biodistribution time-activity curves, area-under-the-curve (AUC) was calculated using trapezoidal integration (KaleidaGraph, Synergy Software) and reported as tissue µCi (injected µCi) -1 (g tissue) -1 × 100 × min. Data are generally reported as mean ± SEM. Pairs were compared by Student's t test. Values of p ≤ 0.05 were considered significant.
Supplementary material
Supplementary material including details of crystallographic conditions is available at http://current-biology.com/supmat/supmatin.htm.
